VivoSim Labs Anticipates 500% Revenue Growth In FY27; Receives $5M Milestone Payment From Eli Lilly
VivoSim Labs, Inc. (Nasdaq: VIVS ) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027, and announced that it has received a $5 million payment from Eli Lilly. VivoSim further announced